ABOGENBIO
Live / Registered — Registered (as of 15 Jul 2025)
What this means for you
Registered since 15 Jul 2025. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 79329638
- Registration number
- 7862325
- Mark type
- Word mark
- Filed
- 01 Nov 2021
- Published for opposition
- 22 Nov 2022
- Registered
- 15 Jul 2025
- Attorney of record
- THOMAS HOXIE
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment or prevention of cancer, and infectious diseases; chemico-pharmaceutical preparations for the treatment or prevention of cancer and infectious diseases; drugs being pharmaceutical preparations for medical purposes for the treatment or prevention of cancer and infectious diseases; biological preparations for the treatment or prevention of cancer and infectious diseases for medical purposes; medicines for the treatment or prevention of cancer and infectious diseases for human purposes; chemical preparations for medical purposes, namely, for the treatment or prevention of cancer and infectious diseases; crude drug being homeopathic pharmaceuticals for the treatment of infectious viral diseases;, lipid particle for nucleotide drug delivery purpose for the treatment or prevention of cancer and infectious diseases; and biochemical medicines for the treatment or prevention of cancer and infectious diseases; dietetic substances being foods and beverages adapted for medical use for the treatment or prevention of cancer and infectious diseases
- Class 042 — Scientific and technological services: Technological research in the field of medical research, specifically for the treatment or prevention of cancer and infectious diseases; quality control, specifically for products for the treatment or prevention of cancer and infectious disease; product quality testing, specifically for products for the treatment or prevention of cancer and infectious diseases; cancer research for medical purposes; pharmaceutical drug development services, specifically for pharmaceutical drugs for the treatment or prevention of cancer and infectious diseases; pharmaceutical product evaluation, namely, drug evaluation, specifically for the treatment or prevention of cancer and infectious diseases; pharmaceutical research services, specifically for products for the treatment or prevention of cancer and infectious diseases; medical research, specifically for the treatment or prevention of cancer and infectious diseases; development of pharmaceutical preparations and pharmaceuticals, specifically for products for the treatment or prevention of cancer and infectious diseases
Owner
Prosecution history
- 19 Feb 2026 — FINAL DECISION TRANSACTION PROCESSED BY IB
- 05 Feb 2026 — FINAL DISPOSITION NOTICE SENT TO IB
- 05 Feb 2026 — FINAL DISPOSITION PROCESSED
- 15 Oct 2025 — FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
- 15 Jul 2025 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 15 Jul 2025 — REGISTERED-PRINCIPAL REGISTER
- 24 Jun 2025 — TTAB RELEASE CASE TO TRADEMARKS
- 24 Jun 2025 — OPPOSITION TERMINATED NO. 999999
- 24 Jun 2025 — OPPOSITION DISMISSED NO. 999999
- 19 Jun 2023 — NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
- 31 May 2023 — NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
- 31 May 2023 — NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
- 19 Apr 2023 — REFUSAL PROCESSED BY IB
- 27 Mar 2023 — OPPOSITION INSTITUTED NO. 999999
- 22 Mar 2023 — OPPOSITION NOTICE (IB REFUSAL) SENT TO IB